Sionna Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
45.2M
on 2026-06-30, from 4.72M on 2024-12-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-03-02. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗
$250.0M
Leerink Partners, agreement of 2026-03-02. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-06 is not read yet.
Cash
3.3 quarters
$63.3M on 2026-06-30 ÷ $19.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2025-02-07 | Public offering | 10,588,233 | $18.00 | not read | 424B4 ↗ |